CryoPort (CYRX) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of CryoPort (NASDAQ: CYRX) in the last few weeks:

• 8/7/2026 – CryoPort had its price target raised by Guggenheim from $12.00 to $16.00. They now have a “buy” rating on the stock.
• 8/7/2026 – CryoPort had its “buy” rating reaffirmed by Roth Capital. They now have a $21.00 price target on the stock.
• 8/7/2026 – CryoPort had its price target raised by Needham & Company LLC from $15.00 to $19.00. They now have a “buy” rating on the stock.
• 8/3/2026 – CryoPort had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 7/24/2026 – CryoPort had its price target raised by BTIG Research from $17.00 to $25.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 23,214 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares in the company, valued at approximately $1,787,259.50. This represents a 60.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 256,441 shares of company stock valued at $4,051,923 over the last three months. Insiders own 9.50% of the company’s stock.

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.